Abcuro
Clinical-stage immunotherapies targeting pathogenic cytotoxic T cells in autoimmune disease.
$66MSeries D
Role not disclosedNE
New Enterprise Associates (NEA)
Activity from announced rounds
Activity in this selectionUnited States · Oct 15, 2026 · Jul 18, 2026
- Rounds participated in
- 3
- Confirmed lead rounds
- — 3 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $335M 3 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in this selectionHorizon3
Runs autonomous AI-driven penetration testing to secure enterprise networks
$250MSeries E
Role not disclosedCentralize
Relationship intelligence platform for enterprise revenue teams
$19MSeed+
Role not disclosed